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A brain-permeable inhibitor of the
neurodegenerative disease target
kynurenine 3-monooxygenase prevents
accumulation of neurotoxic metabolites
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Dysregulation of the kynurenine pathway (KP) leads to imbalances in neuroactive metabo-
lites associated with the pathogenesis of several neurodegenerative disorders, including
Huntington’s disease (HD). Inhibition of the enzyme kynurenine 3-monooxygenase (KMO) in
the KP normalises these metabolic imbalances and ameliorates neurodegeneration and
related phenotypes in several neurodegenerative disease models. KMO is thus a promising
candidate drug target for these disorders, but known inhibitors are not brain permeable. Here,
19 new KMO inhibitors have been identiﬁed. One of these (1) is neuroprotective in a
Drosophila HD model but is minimally brain penetrant in mice. The prodrug variant (1b)
crosses the blood–brain barrier, releases 1 in the brain, thereby lowering levels of 3-
hydroxykynurenine, a toxic KP metabolite linked to neurodegeneration. Prodrug 1b will
advance development of targeted therapies against multiple neurodegenerative and neu-
roinﬂammatory diseases in which KP likely plays a role, including HD, Alzheimer’s disease,
and Parkinson’s disease.
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The kynurenine pathway (KP) (Fig. 1) degrades >95% ofL-tryptophan in mammals and produces neuroactivemetabolites that modulate neurodegeneration and asso-
ciated phenotypes in models of several disorders1–7. Indeed,
studies indicate that KP metabolite imbalances leading to elevated
levels of the free-radical generator 3-hydroxykynurenine (3-HK)
and the excitotoxin quinolinic acid (QUIN) relative to the neu-
roprotective metabolite kynurenic acid (KYNA) (Fig. 1) con-
tribute to pathogenesis8. Upregulation of the central neurotoxic
branch of the KP is linked to expression of proinﬂammatory
cytokines during inﬂammation, which increases expression of
KMO and indoleamine-2, 3-dioxygenase 19. Downregulation of
KMO activity shifts the ﬂux between the two branches of the KP
toward increased KYNA formation, thus generating a neuro-
protective environment (Fig. 1)10. In fact, KMO inhibition ame-
liorates disease phenotypes in ﬂy and mouse models of several
neurodegenerative disorders3–5,7,11. KMO inhibitors are therefore
increasingly considered for strategies to prevent or arrest neu-
rodegeneration9 and as tools to experimentally modulate KP
metabolism4,11–17. However, it should be noted, that complete
elimination of metabolites downstream of KMO is not desirable,
as loss-of-function mutations in downstream enzymes cause
congenital malformations in humans and mice18. Thus, when
targeting the KP, one needs to consider normalisation of meta-
bolite imbalances arising from disease, and not depletion of key
metabolites. Notably, existing KMO inhibitors do not appreciably
enter the brain after systemic administration11. Rather, they act in
the periphery, raising levels of L-KYN in the blood. L-KYN is then
actively transported across the blood–brain barrier and pre-
ferentially converted to neuroprotective KYNA in the central
nervous system (CNS)4,11.
Despite considerable efforts, the development of brain-
permeable KMO inhibitors for experimental and possible
clinical use has not been successful thus far. Such compounds
would be highly desirable as KMO inhibition within the CNS, in
contrast to selective enzyme inhibition in the periphery, results in
a substantive reduction of 3-HK in the brain17,19. For drugs
to pass effectively through cell membranes (including the
blood–brain barrier) solute carrier (SLC)-type transporters are
advantageous20,21. Thus, one strategy for identifying brain-
penetrant compounds is to understand, which endogenous
molecules drugs most resemble22. Here, we used structure-based
virtual screening and compound synthesis alongside cheminfor-
matics to identify brain permeable, drug-like KMO inhibitors,
and to assess their transport mechanism. These insights led to the
development of a prodrug (1b) that releases a neuroprotective
KMO inhibitor within the CNS after peripheral application and
which then directly modulates KP metabolite levels in the brain.
Results
Virtual screening identiﬁes novel KMO inhibitors. A combi-
nation of ligand- and structural-based virtual screening approa-
ches (see supporting information for details) was used to identify
an initial library of >1000 compounds that may be suitable as
potential KMO inhibitors. These compounds were screened for
inhibition of Pseudomonas ﬂuorescens KMO (PfKMO) and Homo
sapiens KMO (HsKMO) using high-throughput assays by mon-
itoring the time-dependent oxidation of NADPH at 340 nm23.
This yielded a total of 19 new inhibitor compounds (IC50 ≤
200 µM) (Table 1). The corresponding structures reveal that the
majority retained a carboxylate moiety that forms interactions
with KMO active-site residues Arg83 and Tyr97 (residues were
labelled according to PfKMO) which are essential for the binding
of previously identiﬁed inhibitor molecules23. The new com-
pounds inhibited both PfKMO and HsKMO with IC50 values
ranging from 400 nM to 400 µM (Table 1 and Supplementary
Fig. 1).
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Fig. 1 The kynurenine pathway of tryptophan metabolism. Enzymes are indicated in italics. The neurotoxic metabolites 3-HK and QUIN are highlighted in
red and the neuroprotective metabolite KYNA in green. The prodrug 1b is transported across the blood–brain barrier via riboﬂavin transporters, where it is
converted, and thereby releases 1. TDO, tryptophan 2,3-dioxygenase. IDO, indoleamine-2,3-dioxygenase
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We next determined crystal structures of KMO in complex
with the novel inhibitors or with L-KYN to inform the design of
small-molecule inhibitors capable of penetrating the blood–brain
barrier. We conjectured that the crystal structures would inform
on which regions of the inhibitor could be modiﬁed as part of a
prodrug strategy to enable transport across the blood–brain
barrier. Co-crystallisation studies of PfKMO with L-KYN or
with the test compounds yielded crystal structures for the
KMO-L-KYN complex (Supplementary Fig. 2; Protein Data Bank
(PDB) code 6FOX) and four KMO inhibitor complexes (1, 4, 9
and 13; Fig. 2 and Supplementary Fig. 3; PDB codes 6FP1, 6FP0,
6FOY and 6FOZ). In each case, the inhibitor was bound in the L-
KYN-binding pocket, with the chlorinated aromatic moiety
occupying a similar position to the substrate L-KYN aniline
group. Furthermore, the carboxylate group of the inhibitor was in
close proximity to PfKMO R83/Y97/N368. However, only
Table 1 Structures and IC50 values of KMO inhibitor compounds
KMO inhibitor
IC50 (μM)
PfKMO
(HsKMO)
IC50 (μM)
PfKMO
(HsKMO)
KMO inhibitor
UPF648 
0.12 ± 0.03 
(0.06 ± 0.04) 
10
3.0 ± 0.1 
(1.6 ± 0.1) 
1
9.3 ± 1.5 
(2.6 ± 0.1) 
11
72.1 ± 1.9 
(144.0 ± 8.0) 
2
130.1 ± 18.7 
(1.5 ± 0.2) 
12
54.0 ± 1.6 
(31.8 ± 1.6) 
3 74.7 ± 8.0 
(2.3 ± 0.4) 
13
0.4 ± 0.02  
(63.1 ± 1.8) 
4
59.83 ± 7.14 
(6.1 ± 0.5) 
14
757 ± 11.8 
(38.8 ± 0.6) 
5
123.4 ± 8.0 
(55.3 ± 2.7) 
15
6.3 ± 0.6 
54.2 ± 3.7 
6
85.6 ± 4.4 
(68.6 ± 4.3) 
16
70.2 ± 2.8 
(207.1 ± 21.5) 
7
100.8 ± 9.1 
(21.3 ± 1.5) 
17
15.9 ± 0.8 
(441.6 ± 34.2) 
8
44.4 ± 5.0 
(36.7 ± 3.1) 
18 2.4 ± 0.3 
(193.4 ± 6.5) 
9
4.3 ± 0.2 
(39.6 ± 2.9) 
19
0.7 ± 0.01 
(54.2 ± 4.3) 
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Compounds 9, 11–13 and 16–19 are structurally similar to the KMO inhibitor 6-(3,4-dichlorophenyl) pyrimidine-4-carboxylic acid13, in which the pyrimidine ring of the reported inhibitor is replaced by an
isosteric furan ring in 9, 11–13 and 16–19. Compound 8 has been described previously as an inhibitor of KMO32
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compound 1 established a network of polar interactions that
closely resembled the enzyme–substrate contacts. This both
rationalises the respective afﬁnity for each of these compounds
and reﬂects the remarkable malleability of the KMO active site.
The structure of the KMO-L-KYN complex was determined at
a resolution of 1.9Å (PDB code 6FOX). The L-KYN substrate is
clearly bound in only one of the KMO monomers in the
asymmetric unit, and resembles the previously reported KMO: L-
KYN complex (PDB 5NAK; Supplementary Fig. 2). However,
there are some differences in the protein:substrate interaction
network, especially surrounding the substrate carboxylate group.
Additional hydrogen bonding interactions are observed between
the L-KYN carboxylate group and both Arg83 and Tyr97, as a
direct consequence of the reorientation of both residues.
Although the L-KYN aromatic moiety is located adjacent to the
ﬂavin isoalloxazine ring as previously reported, an additional
water molecule is present that is located directly above the ﬂavin
C4a/N5. This is accompanied by a slight tilting of the ﬂavin
isoalloxazine. It is interesting to note that recently published
KMO class II inhibitor complexes (PDB 5NAE; 5NAG; 5NAH),
where the ligand mimics both L-KYN and nicotinamide binding,
reveal water molecules in a similar position directly above the C4a
and C10. In each case, the ﬂavin adopts a conformation that is
tilted away from that observed in the 5NAK structure, more akin
to that seen here in the KMO: L-KYN complex. In addition, the
polar network between R83/Y97 and the inhibitor for one of these
(5NAE) is similar to that described here for the L-KYN KMO
complex (Supplementary Fig. 2). The position of the ﬂavin
isoalloxazine appears to be linked to the water molecule above
C4a/N5 which, together with the adjacent water molecule located
above the C10 atom, is likely to mimic the position of individual
oxygen atoms in the proposed C4a peroxoﬂavin adduct. This
suggests nucleophilic attack by the L-KYN occurs on the proximal
oxygen, to generate a transient 3-oxo-L-KYN ﬂavin adduct.
Co-crystallisation studies of PfKMO with the target inhibitor
compounds yielded crystal structures for 4 KMO inhibitor
complexes (1, 4, 9 and 13; Supplementary Fig. 3; PDB codes
6FP1, 6FP0, 6FOY and 6FOZ). A comparison of the inhibitor 1
complex structure with the recently published class I and class II
inhibitors of KMO reveals the latter to be highly similar to the
class I inhibitor recently reported (PDB 5NAB; Supplementary
Fig. 4)24. Although the aromatic moiety of 1 effectively occupies
the hydrophobic binding pocket of KMO, additional space
appears to be available for extending the 1 scaffold with small
additional groups. A larger alkyl group at the methyl-ortho-
substituent orientated away from the ﬂavin is likely to be
accommodated by the enzyme, whereas the structures of the class
II inhibitors have demonstrated that extension of the methyl-
ortho-substituent located in close proximity of the ﬂavin is also
possible, leading to class II type binding and ﬂavin tilting24.
Compounds 1, 4, 9 and 13 competitively inhibit KMO activity
in the absence of hydrogen peroxide production. The KMO
reaction is a random bi–bi mechanism proceeding through a
ternary complex of KMO-bound to L-KYN and NADPH (Sup-
plementary Figs. 5–8, steady-state enzymatic assays are described
in Supplementary Methods) with a turnover value, kcat, of 8.2 ±
0.2 s−1 and Km values for NADPH and L-KYN of 16.9 ± 1.5 and
12.1 ± 1.4 µM, respectively (Supplementary Fig. 6). Product
inhibition studies at saturating and sub-saturating concentrations
of both substrates showed mixed type inhibition patterns under
all conditions (Supplementary Figs. 7 and 8), indicative of a
random bi–bi reaction mechanism. This is in agreement with
previous studies on other KMO enzymes25, and taken together
with previous stopped-ﬂow studies on the oxygen chemistry26
suggests an overall reaction mechanism as shown in Supple-
mentary Fig. 5.
To validate binding modes of the four inhibitors for which
crystal structures were obtained (1, 4, 9 and 13), we investigated
their mechanisms of inhibition (Supplementary Figs. 9–12).
Consistent with the crystal structures, each compound was found
to be a competitive inhibitor of L-KYN. Inhibitor 9 is also a
competitive inhibitor of NADPH, whereas compounds 1, 4 and
13 were mixed type inhibitors with respect to NADPH. Notably,
L-KYN is known to stimulate KMO reduction by NADPH and
other reported KMO inhibitors mimic this effect26. As a
consequence, these inhibitors will accumulate inﬂammatory
hydrogen peroxide (H2O2) following oxidation of KMO-bound
ﬂavin in inhibited enzyme complexes, perhaps limiting their
therapeutic potential. Notably, inhibitors 1, 4, 9, 13 do not
stimulate KMO reduction by NADPH in rapid mixing stopped-
ﬂow assays (Supplementary Fig. 13, Supplementary Table 1).
H2O2 production was not detected with compound 1 and PfKMO
using a coupling reaction with o-dianisidine and horseradish
peroxidase in the presence and absence of L-Kyn (Supplementary
Fig. 14). This suggests that 1, 4, 9, 13 inhibit KMO activity in the
absence of H2O2 production and thus may be preferable for
therapeutic application.
Cheminformatics and in vitro analyses indicate that inhibitor 1
may cross the blood–brain barrier via riboﬂavin transporters.
Standard cheminformatics22 were used to identify if inhibitors 1,
4, 9, 13 have similarities with any endogenous metabolites and
thereby the potential for transport into the brain. Using SLC-type
transporters that the metabolites employ and MACCS encod-
ing22, riboﬂavin was identiﬁed as the most similar metabolite to 1,
with a Tanimoto similarity of 0.62. Inspection of the corre-
sponding structures revealed a common substructure of a tertiary
amine linked to 4-methylbenzyl, methylene and ethylene moi-
eties27. Riboﬂavin, however, is uncharged whereas 1 has a nega-
tive charge. Based on the similarities in chemical structure of 1
and riboﬂavin we surmised that 1 was the most promising can-
didate for transport into the brain by riboﬂavin transporters
(SLC52 family)28, where SLC52A2 is expressed in almost every
tissue29.
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Fig. 2 Structure of the PfKMO active site in complex with 1. Key active site
residues are shown in atom coloured sticks (carbons of PfKMO in blue, 1 in
cyan and the FAD in yellow). Omit electron density map for bound inhibitor
is shown as a green mesh contoured at three sigma. Hydrogen bonding
interactions established between inhibitor and protein are shown as black
dashed lines. All residues shown are conserved in human KMO
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As a promising lead compound, we tested several in vitro
pharmacokinetic parameters (further details and analytical
conditions are described in Supplementary Methods) for 1, and
found that it exhibited good kinetic solubility (Supplementary
Table 2) and metabolic stability in mouse hepatic microsomes
(Supplementary Table 3) and rat hepatocytes (Supplementary
Table 4). As an initial metric for potential brain penetrance we
employed two Madin-Darby canine kidney (MDCK) cell lines—
wild type (WT) and multidrug resistance (MDR1) gene expressing
—to test for cell permeability. Inhibitor 1 exhibited good apparent
permeability in both WT and MDR1 MDCK cells (Apical
to Basolateral Papp values ~15 × 10−6 cm/s; Supplementary
Tables 5 and 6), although the effective efﬂux ratio (Table 2)
indicated that 1 is not a substrate for P-glycoprotein, the efﬂux
protein encoded by MDR1. Notably, inhibitor 1 crossed the test
membrane much more readily in the apical to basolateral
direction than vice-versa, consistent with uptake by a transporter,
complementing our observations above (Supplementary
Tables 5 and 6).
Inhibitor 1 ameliorates neurodegeneration in a Drosophila
model of HD. To test the therapeutic efﬁcacy of 1, we next
employed a widely-used Drosophila melanogaster model of the
inherited neurodegenerative disorder Huntington’s disease (HD)30,
which features pan-neuronal expression of a mutant huntingtin
exon 1 fragment (HTT93Q). We have previously shown that
several KMO inhibitors, including UPF 648 and Ro 61-8048, are
neuroprotective in this Drosophila model3. We thus tested the
ability of 1 to ameliorate loss of photoreceptor neurons in the ﬂy
eye (rhabdomeres) using the pseudopupil assay. Newly enclosed
HTT93Q ﬂies treated with 10 μM or 100 μM of 1 for 7 days
exhibited a signiﬁcant dose-dependent reduction in neuron loss
(10 μM, P < 0.01; 100 μM, P < 0.0001) when compared with
untreated or vehicle (DMSO)-treated animals (Fig. 3a, b). Nota-
bly, the higher dose of 1 prevented ~57% of the neurodegenera-
tion observed in the HD ﬂies. Although the efﬁcacy of 1 may not
be solely due to KMO inhibition in the ﬂy, we have previously
observed similar levels of neuroprotection with other KMO
inhibitors3.
A prodrug strategy permits brain penetrance of inhibitor 1.
Exploration of the stability and brain penetrance of 1 in mice
revealed that a single intravenous bolus administration of 1 at 1
mg/kg in female C57BL/6 mice led to appreciable levels in the
blood at 5 min (3785 ± 639 ng/ml), which was rapidly cleared
from the blood by 60 min (Fig. 3c; Supplementary Table 7), likely
a consequence of high urinary excretion (Supplementary Table 8)
and secondary conjugative metabolism owing to the presence of a
carboxylic acid functionality. Minimal brain penetrance of 1 was
observed at either timepoint (Brain:Blood ratio 0.03). Owing to
this rapid clearance and the limited brain penetrance of 1, a
number of derivatives of 1 were synthesised (1a–h, Table 3)
(experimental details are described in Supplementary Methods).
Compounds 1a–d underwent esteriﬁcation of the carboxyl
group in an effort to produce prodrug variants that reduce
clearance rates and release 1 upon hydrolysis. The remaining
derivatives were designed to test the inhibitory potential of
structurally similar amide (1e–g) or tetrazole (1 h) bioisosteres of
1. As expected, 1a–d did not inhibit KMO in vitro, although 1h
demonstrated similar inhibition to 1 (Table 3). Similar to the
inhibitors above, 1h is bound in the L-KYN-binding pocket, with
the tetrazole moiety in a position similar to the aniline group of L-
KYN (Supplementary Fig. 3e; PDB code 6FPH). The structure of
the 1h complex is very similar to the inhibitor 1 complex, with
the additional bulk of the triazole group accommodated for by
reorientation of R83. This allows a very similar network of polar
contacts between the protein and 1h to be formed.
Pharmacokinetic proﬁles of the 1 prodrugs (1a–d) were
explored after intravenous bolus administration of 1 mg/kg. 1a,
1b and 1c all released 1 in both the blood and brain, whereas 1
was undetectable in 1d-treated animals (Fig. 3c; Supplementary
Table 7). Notably, brain levels of 1 derived from prodrugs 1a and
1b were higher than in the blood 5 min after treatment, with
Brain:Blood ratio of 1.42 and 1.95, respectively. The brain levels
of 1 derived from these compounds dropped markedly 60 min
after treatment, which may indicate efﬂux of 1a and 1b from the
CNS. The isostere 1h exhibited very limited brain penetrance
(Supplementary Table 7) and blood levels were in fact ~50%
lower than those observed for 1, suggesting that this isostere is
cleared even more rapidly from the blood. Inhibitor 1 as well as
prodrugs 1a, 1b and 1c inhibit riboﬂavin uptake by K562 cells
when incubated with riboﬂavin, consistent with the cheminfor-
matic prediction of uptake by the riboﬂavin transporter (Fig. 3d;
Supplementary Fig. 15). Furthermore, 1b showed higher inhibi-
tion of riboﬂavin uptake compared with 1 and the other
prodrugs.
We next extended our pharmacokinetic analyses by testing the
stability and brain penetrance of 1b and released 1 in Wistar rats
(further details are described in Supplementary Methods). In all,
5 mg/kg of 1b was administered intravenously, and levels of 1b
and 1 were measured in the blood and brain at several timepoints
post-administration (5, 15, 30 and 60 min) (Supplementary
Tables 9 and 10). Supporting our data in mice, we found
compound 1 derived from 1b in the brain at all timepoints, with a
maximal Brain:Blood ratio of 3.22 at 15 min (Figure 3e). 1b was
also detected in the brain, although maximal concentration was
5 min post administration, with very low levels of unbound
compound detected in this tissue (1b brain Fu= 0.016)
(Supplementary Table 9). Notably, the unbound brain concen-
trations of 1 (1 brain Fu= 0.30) released from 1b throughout the
timecourse were ~2–20-fold higher than the compound 1 IC50 for
KMO inhibition in brain homogenates from Sprague–Dawley rats
determined via in vitro assays (Supplementary Fig. 16), indicating
that sufﬁcient levels of 1 should be present in the brain to affect
KMO activity.
Peripheral administration of prodrug 1b decreases de novo
synthesis of 3-HK in the CNS. Having found that appreciable
levels of inhibitor 1 are released in the CNS following the intra-
venous administration of the prodrug 1b, we next assessed if this
pharmacological intervention modulates de novo KP metabolism
in the brain in vivo, using a radioactive tracer approach with
[3H]-KYN, which leads to the production of newly formed [3H]-
KYNA, [3H]-3-HK and [3H]-QUIN31. The prodrug (5 mg/kg)
Table 2 Effective efﬂux ratios for test and control
compounds in MDCK cell lines
Compound TPSA(Å2) Effective efﬂux ratio (MDR1/
wild type)
n= 1 n= 2 Mean
Propranolol 1.3 1.3 1.3
Vinblastine 6.7 5.2 5.95
Inhibitor 1 67 0.64 0.84 0.74
Inhibitor 3 71 1.7 1.7 1.7
Inhibitor 5 71 1.5 1.4 1.45
Inhibitor 6 37 0.81 0.43 0.62
Inhibitor 8 67 0.65 1.3 0.975
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was administered intravenously to rats, immediately followed by
an intrastriatal infusion of [3H]-KYN. Tritiated KP metabolites
were analysed after 1 h. A signiﬁcant ~70% reduction (P < 0.01) in
[3H]-3-HK was observed (Fig. 3f) in parallel with minor increases
in [3H]-QUIN and [3H]-3-KYNA (data not shown)—mirroring
the results using a focal intracerebral injection of a KMO
inhibitor17. In contrast, no reduction of [3H]-3-HK was
detected in rats receiving an intravenous infusion of Ro 61-8048
(50 mg/kg), a KMO inhibitor that does not cross the blood–brain
barrier4,12. Taken together, these data suggest that compound 1
released locally by the prodrug 1b effectively inhibits KMO
activity in the CNS.
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Fig. 3 In vivo analysis of inhibitor 1 and its derivatives. a Representative pseudopupil images from 7 day old wild-type control ﬂies and HD ﬂies (treated with
either vehicle (DMSO) or 10 μM/100 μM inhibitor 1). Control ﬂies exhibit seven visible rhabdomeres per ommatidium, whereas degeneration of these
photoreceptor neurons is observed in HD ﬂies. b Rhabdomere quantiﬁcation of HTT93Q ﬂies treated with inhibitor 1. Newly enclosed HTT93Q ﬂies were
treated with 10 μM or 100 μM inhibitor 1 for 7 days. n= 11–14 ﬂies per condition as labelled in the ﬁgure. *P < 0.05, **P < 0.01, ****P < 0.0001, ANOVA
with Newman–Keuls post hoc test. Untreated and DMSO-treated groups served as controls. c The concentration of inhibitor 1 detected in the brain at
5 min and 60min after a single intravenous administration in the mouse. The concentration of inhibitor 1 in the blood was plotted as ng/mL and in the brain
was plotted as ng/g. The number above each column is the mean brain:blood ratio of inhibitor 1 detected in the sample, NR= no result as concentration
below limit of detection (n= 3 mice, **P < 0.01, ANOVA with Tukey post hoc test). d The effect of inhibitor 1 and prodrugs on the ﬂuorescence of K562
cells incubated with riboﬂavin (or without as a control) and read over 300 s (n= 300). e The concentration of inhibitor 1 detected in the brain and blood
after single intravenous administration of prodrug 1b in the rat (n= 3 rats). The number above each column is the mean brain:blood ratio of inhibitor 1
detected in the sample. f Percentage of [5-3H]-KYN that is metabolised into [3H]-3-HK in the striatum of awake rats 1 h after an intravenous injection of
vehicle, prodrug 1b, or Ro 61-8048. n= 6–10 rats as indicated in the ﬁgure panel, **P < 0.01, one-way ANOVA with Bonferroni’s multiple comparisons post
hoc test. In panels c through e the values are expressed as the mean ± SEM
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Discussion
The therapeutic potential of targeting KMO in neurodegenerative
diseases is supported by several studies published over the past
~15 years using genetic and pharmacological approaches. Indeed,
a ﬂurry of recent activity has led to the generation and char-
acterisation of a number of novel, potent KMO inhibitors, which
are efﬁcacious in a variety of disease models4,7,13,14,26. However, a
limitation of these compounds when considering neurodegen-
erative disorders is that none appreciably penetrate the
blood–brain barrier to enter the brain. While inhibition of KMO
in the blood is likely sufﬁcient to increase CNS levels of neuro-
protective KYNA via increased transport of L-KYN to the brain4,
KMO inhibition in the brain would have the added beneﬁt by
decreasing levels of the downstream neurotoxic metabolites. Thus
the development of brain-penetrant KMO inhibitors is of great
interest to the neurodegeneration research community, and holds
the promise of delivering particularly robust neuroprotection.
Herein, we present the ﬁrst characterisation of a brain-penetrant
KMO inhibitor.
Our studies support the notion that 1 is a neuroprotective
KMO inhibitor that can be delivered to the brain using a prodrug
strategy, as exempliﬁed by 1b. We show that this approach can
lead to inhibition of KMO in the brain, thereby dramatically
decreasing de novo 3-HK synthesis in the CNS. This work will
form the basis for future studies, detailing the pharmacokinetics
and pharmacodynamics of these compounds, and testing of their
therapeutic potential. The hope is that this will lead to clinical
therapies for neurodegenerative disease.
Methods
Screening of potential KMO inhibitors. Small-molecule compounds were sup-
plied by Biofocus (Charles River Laboratories International Inc., MA, USA), which
were identiﬁed in silico as potential inhibitors (further details are described in the
Supplementary Methods). Initial inhibition assays were performed against Pseu-
domonas ﬂuorescens KMO (PfKMO) and Homo sapiens KMO (HsKMO) by
monitoring the time-dependent absorbance change of NADPH at 340 nm. Puriﬁed
KMO protein (200 nM) was incubated in 100 µL reaction buffer (20 mM potassium
phosphate pH 8.0, 7 mM 2-mercaptoethanol) containing 100 μM NADPH, 100 μM
L-Kyn and 20 μM potential inhibitors in 96-well plates. The change in absorbance
at 340 nm was measured using a Synergy™ HT microplate reader (BioTek, VT,
USA) for 25 min at 37 °C. The inhibitors identiﬁed in the initial screens were
validated and re-assayed individually in a 1 cm path-length quartz micro cuvette.
IC50 values of potential compounds towards PfKMO or HsKMO <200 μM were
considered as indicative of KMO inhibition. Suppliers for target inhibitor com-
pounds are listed in Supplementary Table 11.
Expression and puriﬁcation of KMO. The codon optimised gene for P. ﬂuorescens
KMO (accession number: Q84HF5) containing mutations of two cysteine residues
(252 and 461) to serine was synthesised (GeneArt, ThermoFisher), sub-cloned into
pET17b and transformed into E. coli BL21 (DE3) competent cells for expression.
Protein was expressed by growing transformed cells in auto induction LB medium
(FormediumTM, glucose/lactose ratio 1:4) containing 100 µg/mL ampicillin for 24 h
at 22 °C. Cells were harvested by centrifugation at 6000 g for 15 min at 4 °C,
resuspended in lysis buffer (20 mM HEPES pH 7.5, 10 mM NaCl, 1 mM DTT)
supplemented with protease inhibitor cocktail and lysed by sonication (15 × 15 s).
The cell lysate was centrifuged at 180,000 g for 1 h at 4 °C to remove cell debris.
The soluble cell lysate was loaded onto a Q-sepharose column equilibrated with
anion exchange buffer (20 mM HEPES pH 7.5, 1 mM DTT with 10 mM NaCl) and
bound protein was eluted with a gradient (ﬁve column volumes) of increasing NaCl
concentration from 50 to 100 mM in anion exchange buffer. Fractions containing
KMO were pooled and precipitated in 50% saturated ammonium sulphate by
adding precipitation buffer (20 mM HEPES pH 7.5, 3 M ammonium sulphate,
1 mM DTT). The precipitated protein was pelleted by centrifugation at 12,000 g for
20 min, resuspended in a small volume of size exclusion buffer (20 mM HEPES pH
7.0, 150 mM sodium acetate, 1 mM DTT) and passed down a Superdex 75 column.
Pure PfKMO was pooled and stored at −80 °C. Homo sapiens KMO (HsKMO) was
expressed and puriﬁed as previously described23. Cell pellets were thawed at room
temperature and resuspended in Lysis/Solubilisation buffer (20 mM potassium
phosphate buffer pH 7.5, 10% glycerol, 1% n-dodecyl b-D-maltoside (DDM),
300 mM NaCl, 7 mM 2-mercaptoethanol, 1 mM EDTA and 50 μM FAD-
containing protease inhibitors and Benzonase (10,000 dilution). Cells were lysed by
sonication on ice and cell debris was removed by centrifugation at 15,000 rpm for
30 min. Soluble lysate was incubated with pre-equilibrated glutathione uniﬂow
resin (Clontech). The resin was then packed and washed with washing buffer
(20 mM potassium phosphate buffer pH 7.5, 10% glycerol, 0.015% DDM, 150 mM
NaCl, 7 mM 2-mercaptoethanol, 1 mM EDTA, 1 mM PMSF, 50 μM FAD). 0.5 mL
fractions were eluted with elution buffer (washing buffer supplemented with
20 mM reduced glutathione, pH 7.0) and fractions containing GST-KMO were
pooled, concentrated and loaded onto a Superdex 200 (10/30) size exclusion
chromatography column (GE Healthcare). The GST part of the fusion protein was
cleaved from HsKMO by overnight incubation and gentle shaking with thrombin
(1 unit/100 μg of protein) before size exclusion chromatography. Pure GST-
HsKMO or cleaved HsKMO were pooled and stored at −80 °C. The purity of ﬁnal
fractions was analysed by SDS–PAGE.
Crystallisation of PfKMO. To obtain PfKMO structures in complex with substrate
or inhibitor puriﬁed protein in 20 mM HEPES pH 7.0, 20 mM sodium acetate,
1 mM DTT was incubated with each small molecule (1 mM) overnight at 4 °C on a
roller shaker. The solution was clariﬁed by centrifugation prior to concentrating to
a ﬁnal protein concentration of 12–15 mg/mL. Crystals of KMO-ligand complexes
were obtained by mixing 200 nL of protein with 200 nL of D5 condition (0.2 M
sodium acetate trihydrate, 0.1 M sodium cacodylate pH 6.5, 18% w/v PEG 8000) in
SG1 screens (Molecular Dimensions Ltd., Newmarket, UK). Crystals were obtained
by incubation at 4 °C for 72 h using the sitting drop vapour diffusion technique
with microseeding from KMO crystals generated previously.
Data were collected from single cryo protected crystals of PfKMO at beamlines
i03, i04 and i04-1 (Diamond Light Source). All data were indexed, scaled and
subsequently integrated with Xia2. Structure determination was initially performed
by molecular replacement in Phaser using a search model derived from the
previously solved Saccharomyces cerevisiae KMO (4J33). A combination of
automated and manual rebuilding and reﬁnement in Phenix and COOT were used
to produce each of the reﬁned models. Validation with both Molprobity and
PDB_REDO were integrated into the iterative rebuild process. Complete data
collection and reﬁnement statistics are available in Supplementary Table 12.
Stopped-ﬂow spectrophotometry. The reduction rate of the ﬂavin cofactor by
NADPH was measured using a stopped-ﬂow spectrophotometer (Applied Photo-
physics Ltd), which was housed in an anaerobic glovebox (Belle Technology).
Table 3 Structures, IC50 values and calculated SlogP values
for compound 1 and derivatives
Compound Structure IC50 (μM) SlogP HsKMO Pf KMO
1 2.60 ± 0.12 9.31 ± 1.49 1.77
1a ∼500
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>500 1.86
1b >500 >300 2.25
1c >300 >300 2.63
1d >>300 ~200 3.02
1e ~300 >300 1.77
1f >300 >300 1.43
1g >300 >300 1.17
1h 1.28 ± 0.08 16.96 ± 0.43 1.40
SlogP values calculated using KNIME/RDKit using implementation described33
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Anaerobic mixtures of 20 μM PfKMO in the presence and absence of saturating
concentrations of L-KYN (500 µM) or inhibitor (more than 100 times of Ki
according to Supplementary Table 13, 1: 120 µM, 4: 700 µM, 9: 60 µM, 13: 6 µM,
1 h: 220 µM) were mixed against anaerobic NADPH (4 mM) at 25 °C. The
reduction of the ﬂavin was monitored by the decrease in the absorbance of the
ﬂavin at 450 nm and transients were ﬁtted to either double or triple exponentials.
Hydrogen peroxide production. H2O2 production rates from PfKMO inhibitor
complexes were performed using a horseradish peroxidase (HRP) assay. NADPH
consumption rate was measured in the presence and absence of an excess of KMO
inhibitors (400 μM). For determination of H2O2 production rates, PfKMO (0.1 μM)
was incubated with 100 μM NADPH, 200 μM L-KYN, 400 μM o-dianisidine and
∼5 units HRP in the presence and absence of excess KMO inhibitors. The rate of
oxidation of o-dianisidine by H2O2, catalysed by HRP, was monitored at 440 nm
(Δε 440 nm= 11.3 mM−1 cm−1). To eliminate the L-Kyn competition binding
effect, the H2O2 production rates of KMO inhibitors were also measured without
L-Kyn with the same method.
Mouse brain penetration studies. Inhibitor 1 (and prodrugs 1a, 1b, 1c and 1d)
was dosed as a bolus solution intravenously at 1 mg free base/kg (dose volume:
5 mL/kg; dose vehicle: 5% DMSO; 95% saline (inhibitor 1) or 5% DMSO; 40%
PEG400; 55% MilliQ H2O (prodrugs 1a, 1b, 1c and 1d)) to female C57BL6 mice
(n= 6). At 5 min and 60 min following intravenous bolus injection of test com-
pound, mice (n= 3/timepoint) were placed under terminal anaesthesia with iso-
ﬂuorane. A blood sample was taken by cardiac puncture, the mice decapitated and
the brain removed. Brain weight was noted and each brain homogenised with two
volumes of methanol (2 mL/g brain). Each blood sample was diluted with distilled
water (1:10). Diluted blood and the brain homogenates were then stored frozen
until preparation and analysis by UPLC-MS/MS. For each mouse at each timepoint
for 1, the concentration in brain (ng/g) was divided by the concentration in blood
(ng/mL) to give a brain:blood ratio. The mean value obtained was quoted. For
prodrugs 1a to 1d, only the concentration of 1 in blood (ng/mL) and brain (ng/g)
was reported.
Rat brain penetration studies. Prodrug 1b was dosed as a bolus solution intra-
venously at 5 mg free base/kg (dose volume: 1 mL/kg; dose vehicle: 10% DMSO;
60% PEG400; 30% MilliQ H2O) to male Han Wistar rats (n= 12). At 5, 15, 30 and
60 min following intravenous bolus injection of prodrug 1b, mice (n= 3/time-
point) were placed under terminal anaesthesia with isoﬂuorane. A blood sample
was taken by cardiac puncture, the mice decapitated and the brain removed. Brain
weight was noted and each brain homogenised with two volumes of methanol:
water (1:1; 2 mL/g brain). Each blood sample was diluted with distilled water (1:2).
Diluted blood and the brain homogenates were then stored frozen until prepara-
tion and analysis by UPLC-MS/MS, monitoring for prodrug 1b and production of
inhibitor 1. For each rat at each timepoint for 1, the concentration in brain (ng/g)
was divided by the concentration in blood (ng/mL) to give a brain:blood ratio. The
mean value obtained was quoted.
Bioanalysis by ultra-performance chromatography and tandem mass spec-
trometry. A rapid and sensitive ultra-performance chromatography/tandem mass
spectrometry (UPLC-MS/MS) method was developed and validated for the
determination of inhibitor 1 and prodrug 1b (rat only). Chromatographic analysis
was conducted on a Waters Acquity™ UPLC system. Chromatographic separation
was performed with an Acquity™ UPLC BEH C18 column (50 × 2.1 mm, 1.7 µm,
130Å; Waters Corp.) maintained at 40 °C in a column oven. The mobile phase
consisted of water with 0.01% formic acid and ACN with 0.01 % formic acid and it
was delivered at a ﬂow rate of 0.6 mL/min under gradient eluent conditions within
an analysis cycle time of 3 min. The mass detection was conducted on a Waters
Xevo™ TQs mass spectrometer equipped with a ScanWave™ technology. Quanti-
tation of the analyte was performed in electrospray positive ionisation mode (ESI+)
using multiple reaction monitoring. The optimised fragmentation transition was
m/z= 270.17 → 196.19 (mouse) or m/z= 270.17 → 223.76 (rat) for inhibitor 1
and m/z= 297.83 → 195.74 for prodrug 1b (rat).
Sample extraction for blood and brain homogenate was by protein precipitation
(1:3 or 1:6) using ACN containing suitable internal standard. Extracts were
vortexed followed by centrifugation (2800 rpm for 10 min). An aliquot of each
supernatant was then diluted two-fold in distilled water ready for analysis by
UPLC-MS/MS.
The weighted 1/x2 calibration line was linear in the dynamic range of
1–5000 ng/mL for inhibitor 1 and 1–1000 ng/mL for prodrug 1b with a correlation
coefﬁcient (r2) > 0.99 (inhibitor 1) or 0.98 (prodrug 1b). The quality control
samples (QC) were prepared by using the same spiking scheme as the calibration
samples and up to four different target concentration brain levels: 2 ng/mL
(LQC), 40 ng/mL (MQC), 100 ng/mL (HQC) and 2000 ng/mL. Data collection,
peak integration and calculations were performed using MassLynx software,
version 2.1.
Therapeutic efﬁcacy of inhibitor 1 in Drosophila melanogastermodel. Flies were
kept on standard maize food at 25 °C with a 12:12 light/dark cycle. HTT93Q exon 1
expressing ﬂies were generated by crossing female virgins carrying the
UASHTT93Qexon1 transgene30 (a gift of Larry Marsh and Leslie Thompson,
University of California, Irvine) to males of elavGAL4 [c155] driver line, obtained
from the Bloomington Drosophila Stock Center. For the drug feeding experiments,
inhibitor 1 was dissolved in dimethylsulfoxide (DMSO) and added to maize media
at the experimental concentrations. Newly emerged HTT93Q exon 1 ﬂies were
transferred to media supplemented with DMSO or drug and changed daily to fresh
media for the duration of the experiment. At day 7, rhabdomeres were scored as
previously described5. In brief, ﬂies were anaesthetised with CO2, their heads
removed and then mounted on microscope slides using nail polish. Rhabdomeres
were examined using a Nikon Optiphot-2 light microscope, with ~ 80 ommatidia
scored per ﬂy.
Intrastriatal injection of [5-3H]-kynurenine. The radioactive tracer method
previously described by Guidetti et al. (1995)31 was used to study acute KP
metabolism in the brain in vivo. To this end, adult male Sprague–Dawley rats
(weighing 270–300 g) were anesthetized with isoﬂurane using a vaporiser (induc-
tion dose 5%, maintenance dose 2%, v/v, in 100% oxygen) and placed in a ste-
reotaxic frame. A guide cannula was positioned unilaterally over the striatum (AP:
0.8 mm anterior to bregma, ML: ±2.7 mm from midline, DV: 4.5 mm below dura;
hemispheres counter-balanced) and secured to the skull with acrylic dental cement.
On the next day, rats were injected intravenously with either vehicle or prodrug 1b
(5 mg/kg), then immediately rats were infused intrastriatally with 6 µL of [3H]-
kynurenine (2.5 µCi) over 10 min using a microinfusion pump. To assess the effect
of KMO inhibition in the striatum, all animals were killed 1 h after the start of the
[3H]-kynurenine infusion, and their brain was quickly removed. The striata were
rapidly dissected out on ice, frozen on dry ice and stored at 80 °C until processed.
After thawing, tritiated KP metabolites were detected and analysed as described
previously31. The production of newly formed [3H]-KYNA, [3H]-3-HK and [3H]-
QUIN was expressed as a percentage of the total radioactivity recovered per
striatum. HPLC conditions: 100 mM ammonium phosphate (11.5 g/L); 100 mM
glacial acetic acid (5.75 mL/L= 6.03 g/L); 1.5 mM 1-octanesulfonic acid (0.34 g/L);
4% ACN pH 3.2 with 1:1 H3PO4/acetic acid. The mobile phase was ﬂown at 1.2 ml/
min (Waters 515 HPLC Pump) through YMC-Pack Pro C18 (250 × 4.6 mm) col-
umn and detected with UV (Applied Biosystems 785A Absorbance Detector) at
254 nm then mixed with LabLogic FlowLogic U scintillation ﬂuid ﬂowing at
2.7 mL/min and radiation was detected (Berthold Technologies FlowStar LB514).
Competition assays for the uptake of riboﬂavin and KMO inhibitors. Riboﬂavin
transporters are equilibrative rather than concentrative, and the uptake of the
inhibitors would be hard to measure directly. To assess whether the KMO inhi-
bitors were substrates for riboﬂavin transporters, we assessed their ability to
compete with riboﬂavin for uptake into cells. Riboﬂavin is intensely ﬂuorescent,
and is taken up in human cells by three main transporters SLC52A1, SLC52A2 and
SLC52A328. SLC52A2 is the most highly expressed, but each has a Km for riboﬂavin
of ~1 μM. Consequently, we incubated cells with 1 μM riboﬂavin in the absence
and presence of the various KMO inhibitors. There was a background ﬂuorescence
of some 100 relative ﬂuorescence units. Cellular uptake was quite heterogeneous,
but Supplementary Fig. 13 shows that for each of the three inhibitors illustrated,
there is an inhibition of uptake. The data are summarised in Fig. 3c, and are
consistent with the view that at least some of the KMO inhibitor uptake is likely to
go via riboﬂavin transporters.
Statistics and reproducibility. Statistical analyses were performed using Prism 7
(GraphPad Software Inc). ANOVA with Newman–Keuls post hoc tests were used
for analyses of rhabdomere degeneration, with P values < 0.05 considered sig-
niﬁcant for the comparisons. For analysis of brain penetration of compounds,
ANOVA with Tukey post hoc tests were used and P values < 0.01 were considered
signiﬁcant. For assessment of de novo 3-HK synthesis via [5-3H]-kynurenine,
ANOVA with Bonferroni’s multiple comparisons post hoc tests were employed
with P values < 0.01 considered signiﬁcant. All the measurements were done with
at least three repeats. However, owing to sensitivity limitations in mass spectro-
metry detection, two measurements of brain penetration were restricted to only
two replicates. All the values are expressed as the mean ± SEM or
mean ± SD.
Ethical regulations. The pharmacokinetics studies were performed at the Drug
Discovery Unit, School of Life Sciences, University of Dundee, UK. All regulated
procedures on living animals in the DDU were carried out under the authority of a
project licence issued by the Home Ofﬁce under the Animals (Scientiﬁc Proce-
dures) Act 1986, as amended in 2012 (and in compliance with EU Directive EU/
2010/63). Licence applications were approved by the University’s Ethical Review
Committee (ERC) before submission to the Home Ofﬁce. The ERC has a general
remit to develop and oversee policy on all aspects of the use of animals on Uni-
versity premises and is a sub-committee of the University Court, its highest gov-
erning body. For the mouse studies female C57Bl6 mice were employed
(6–12 weeks old). For the rat studies male Han Wistar rats were employed
(7–9 weeks old).
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Analysis of de novo 3-HK synthesis was performed at the Maryland Psychiatric
Research Center, University of Maryland, USA. Animals were housed in a
temperature-controlled, AAALAC-approved animal facility on a 12/12h-light/dark
cycle with unlimited access to food and water. The experimental protocol was
approved by the Institutional Animal Care and Use Committee of the University of
Maryland School of Medicine. Male, Sprague–Dawley rats were employed (10-
week old).
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The atomic coordinates and experimental data (codes 6FP0, 6FP1, 6FPH, 6FOX, 6FOY &
6FOZ) have been deposited in the Protein Data Bank (www.wwpdb.org). Raw data used
for Fig. 3 are available in Supplementary Data 1. All other data are available from the
corresponding author on reasonable request.
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